| Drug Type Small molecule drug | 
| Synonyms MK 4074 | 
| Target | 
| Action inhibitors | 
| Mechanism ACC2 inhibitors(Acetyl-CoA carboxylase 2 inhibitors) | 
| Therapeutic Areas | 
| Active Indication- | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhasePendingPhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC33H31N3O6 | 
| InChIKeyWDBNGXLHMZSUEI-UHFFFAOYSA-N | 
| CAS Registry1039758-22-9 | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Metabolic dysfunction-associated steatotic liver disease | Phase 1 | - | 26 Oct 2011 | |
| Diabetes Mellitus | Phase 1 | United States  | - | |
| Fatty Liver | Phase 1 | United States  | - | 
| Phase 1 | 31 | (MK-4074) | mvtopbbtmr(wywmadyspj) = mnicvipvcr lmobsgevxo  (wkdlvdzjbo, xvkoszswyp - mxhwurorqn) View more | - | 25 Mar 2016 | ||
| (Pioglitazone) | mvtopbbtmr(wywmadyspj) = nlhhbhhehi lmobsgevxo  (wkdlvdzjbo, rjmxemiqow - gvhewwbumv) View more | 





